open access
Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension
open access
Abstract
Abstract
Keywords
endothelins; acute pulmonary embolism; chronic thromboembolic hypertension


Title
Potential role of endothelin in patients with acute pulmonary embolism and chronic thromboembolic pulmonary hypertension
Journal
Advances in Respiratory Medicine
Issue
Article type
Review paper
Pages
159-165
Published online
2009-03-16
Bibliographic record
Pneumonol Alergol Pol 2009;77(2):159-165.
Keywords
endothelins
acute pulmonary embolism
chronic thromboembolic hypertension
Authors
Justyna Pedowska-Włoszek
Maciej Kostrubiec
Piotr Pruszczyk


- Masaki T. The discovery of endothelins. Cardiovasc Res. 1998; 39(3): 530–533.
- Gawlik R, Ziora D, Rogala E, et al. Zawartość endoteliny-1 w popłuczynach oskrzelowo-pęcherzykowych u chorych na wybrane choroby dróg oddechowych. Pneumonol Alergol Pol. 1997; 65: 333–337.
- Passowicz-Muszyńska E, Jankowska R, Szeliga W. Stężenia endoteliny w surowicy chorych na astmę oskrzelową atopową. Pneumonol Alergol Pol. 1999; 67: 17–21.
- Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991; 114(6): 464–469.
- Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest. 2007; 131(1): 101–108.
- Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004; 24(3): 353–359.
- McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25(2): 244–249.
- Galiè N, Torbicki A, Barst R, et al. Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004; 25(24): 2243–2278.
- Nakano J, Takizawa H, Ohtoshi T, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332(6163): 411–415.
- Packer M, Greenberg B, Massie B, et al. Deleterious Effects of Hydralazine in Patients with Pulmonary Hypertension. New England Journal of Medicine. 1982; 306(22): 1326–1331.
- Blais V, Fugère M, Denault JB, et al. Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett. 2002; 524(1-3): 43–48.
- Battistini B, Dussault P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Pulm Pharmacol Ther. 1998; 11(2-3): 79–88.
- Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol Pharm Bull. 2001; 24(11): 1219–1230.
- Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004; 61(2): 227–237.
- Attinà T, Camidge R, Newby DE, et al. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart. 2005; 91(6): 825–831.
- Macquin-Mavier I, Levame M, Istin N, et al. Mechanisms of endothelin-mediated bronchoconstriction in the guinea pig. J Pharmacol Exp Ther. 1989; 250(2): 740–745.
- Shichiri M, Kato H, Marumo F, et al. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension. 1997; 30(5): 1198–1203.
- Thiemermann C, Lidbury PS, Thomas GR, et al. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit. J Cardiovasc Pharmacol. 1989; 13 Suppl 5: S138–41; discussion S142.
- Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer. 2003; 88(2): 163–166.
- Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem. 1993; 268(25): 19126–19133.
- Goldie RG. Endothelin receptor subtypes: distribution and function in the lung. Pulm Pharmacol Ther. 1998; 11(2-3): 89–95.
- Dupuis J, Cernacek P, Tardif JC, et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996; 94(7): 1578–1584.
- Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008; 31(2): 407–415.
- Sauvageau S, Thorin E, Caron A, et al. Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med (Maywood). 2006; 231(6): 840–846.
- Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 1993; 91(4): 1367–1373.
- Lal H, Woodward B, Williams KI. Investigation of the contributions of nitric oxide and prostaglandins to the actions of endothelins and sarafotoxin 6c in rat isolated perfused lungs. Br J Pharmacol. 1996; 118(8): 1931–1938.
- Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002; 165(3): 398–405.
- Hocher B, Schwarz A, Fagan KA, et al. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol. 2000; 23(1): 19–26.
- Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part II: risk stratification, treatment, and prevention. Circulation. 2003; 108(23): 2834–2838.
- Goldhaber SZ, Elliott CG. Acute pulmonary embolism: part I: epidemiology, pathophysiology, and diagnosis. Circulation. 2003; 108(22): 2726–2729.
- Gurewich V, Cohen ML, Thomas DP. Humoral factors in massive pulmonary embolism: an experimental study. Am Heart J. 1968; 76(6): 784–794.
- Sofia M, Faraone S, Alifano M, et al. Endothelin abnormalities in patients with pulmonary embolism. Chest. 1997; 111(3): 544–549.
- Schini VB, Hendrickson H, Heublein DM, et al. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol. 1989; 165(2-3): 333–334.
- Halim A, Kanayama N, el Maradny E, et al. Endothelin-1 increased immunoreactive von Willebrand factor in endothelial cells and induced micro thrombosis in rats. Thromb Res. 1994; 76(1): 71–78.
- Dschietzig T, Laule M, Alexiou K, et al. Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction. Crit Care Med. 1998; 26(3): 510–517.
- Simon M, Battistini B, Joo Kim Y, et al. Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. Respir Physiol Neurobiol. 2003; 138(1): 97–106.
- Tsang J, Battistini B, Dussault P, et al. Biphasic release of immunoreactive endothelins following acute pulmonary thromboembolism in pigs. J Cardiovasc Pharmacol. 2000; 36(5 Suppl 1): S221–S224.
- Lee JH, Chun YG, Lee IC, et al. Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Am J Respir Crit Care Med. 2001; 164(7): 1282–1287.
- Lee JH, Kim S, Park BH, et al. The effect of a combination of inhaled nitric oxide and an endothelin A-.receptor antagonist on hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Lung. 2005; 183: 139–149.
- Tanus-Santos JE, Gordo WM, Udelsmann A, et al. Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs. Chest. 2000; 118(1): 175–179.
- Tsang JYC, Lamm WJE, Neradilek B, et al. Endothelin receptor blockade does not improve hypoxemia following acute pulmonary thromboembolism. J Appl Physiol (1985). 2007; 102(2): 762–771.
- Torbicki A, Kurzyna M. Nadciśnienie płucne. In: Szczeklik A. ed. Choroby wewnętrzne. . Medycyna Praktyczna. 2006: 351–359.
- Kaczyńska A, Kostrubiec M, Pacho R, et al. Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism. Thromb Res. 2008; 122(1): 21–25.
- Reesink H, Lutter R, et al. Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004; 24: 110.
- Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002; 105(9): 1034–1036.
- Bresser P, Pepke-Zaba J, Jaïs X, et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc. 2006; 3(7): 594–600.
- Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005; 128(4): 2599–2603.
- Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006; 28(1): 138–143.
- Jais X, Ghofrani A, Hoeper MM, et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): A randomized, placebo-controlled trial — BENEFIT. Am. J. Respir. Crit. Care Med. 2007; 175: A896.